Last reviewed · How we verify

Venlafaxine and Lamotrigine

University Health Network, Toronto · FDA-approved active Small molecule

Venlafaxine and Lamotrigine is a SNRI + anticonvulsant combination Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved for Major depressive disorder (treatment-resistant or augmentation), Bipolar depression, Anxiety disorders.

Venlafaxine inhibits reuptake of serotonin and norepinephrine while lamotrigine stabilizes neuronal membranes by blocking sodium channels and modulating glutamate release, together providing antidepressant and mood-stabilizing effects.

Venlafaxine inhibits reuptake of serotonin and norepinephrine while lamotrigine stabilizes neuronal membranes by blocking sodium channels and modulating glutamate release, together providing antidepressant and mood-stabilizing effects. Used for Major depressive disorder (treatment-resistant or augmentation), Bipolar depression, Anxiety disorders.

At a glance

Generic nameVenlafaxine and Lamotrigine
SponsorUniversity Health Network, Toronto
Drug classSNRI + anticonvulsant combination
TargetSerotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation
ModalitySmall molecule
Therapeutic areaPsychiatry / Neurology
PhaseFDA-approved

Mechanism of action

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic concentrations of both neurotransmitters to alleviate depression and anxiety. Lamotrigine is an anticonvulsant that reduces excitatory glutamate transmission and stabilizes neuronal firing, providing additional mood-stabilizing and neuroprotective benefits. This combination is used off-label or in clinical practice to enhance efficacy in treatment-resistant depression and bipolar disorder.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Venlafaxine and Lamotrigine

What is Venlafaxine and Lamotrigine?

Venlafaxine and Lamotrigine is a SNRI + anticonvulsant combination drug developed by University Health Network, Toronto, indicated for Major depressive disorder (treatment-resistant or augmentation), Bipolar depression, Anxiety disorders.

How does Venlafaxine and Lamotrigine work?

Venlafaxine inhibits reuptake of serotonin and norepinephrine while lamotrigine stabilizes neuronal membranes by blocking sodium channels and modulating glutamate release, together providing antidepressant and mood-stabilizing effects.

What is Venlafaxine and Lamotrigine used for?

Venlafaxine and Lamotrigine is indicated for Major depressive disorder (treatment-resistant or augmentation), Bipolar depression, Anxiety disorders.

Who makes Venlafaxine and Lamotrigine?

Venlafaxine and Lamotrigine is developed and marketed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).

What drug class is Venlafaxine and Lamotrigine in?

Venlafaxine and Lamotrigine belongs to the SNRI + anticonvulsant combination class. See all SNRI + anticonvulsant combination drugs at /class/snri-anticonvulsant-combination.

What development phase is Venlafaxine and Lamotrigine in?

Venlafaxine and Lamotrigine is FDA-approved (marketed).

What are the side effects of Venlafaxine and Lamotrigine?

Common side effects of Venlafaxine and Lamotrigine include Nausea, Headache, Dizziness, Insomnia or somnolence, Rash (lamotrigine-related), Sexual dysfunction.

What does Venlafaxine and Lamotrigine target?

Venlafaxine and Lamotrigine targets Serotonin transporter, norepinephrine transporter, voltage-gated sodium channels, glutamate modulation and is a SNRI + anticonvulsant combination.

Related